Treatment with apalutamide (Erleada) resulted in a rapid and substantial decline in PSA, and greater magnitude of PSA decline correlated with improvement in several oncologic endpoints, results from the phase III SPARTAN study showed.
Cheryl Guttman Krader
A study investigating associations between statin use and prostate cancer outcomes provides further evidence that the medication may have race-related benefit, providing protective effects among Caucasian men but not in African-Americans.
The protein Kidney Injury Molecule 1 shows promise as a blood-based biomarker for renal cell carcinoma diagnosis and for predicting overall survival after RCC diagnosis.
Although it may not be the last word on the topic, new research sheds light on the choice of cytoreductive nephrectomy and/or targeted therapy in patients with metastatic renal cell carcinoma.
Findings of a multi-institutional cohort study provide further evidence that favorable outcomes can be achieved by carefully selected patients with muscle-invasive bladder cancer who forgo radical cystectomy after achieving a clinical complete response to neoadjuvant chemotherapy.
Personally tailored intervention generates patient interest, QoL improvements.
Benefit evident regardless of metastasis site, phase III analysis shows.
~40% of sipuleucel-T recipients in lowest PSA quartile alive after 5 years.
Although active surveillance for prostate cancer is on the rise in younger, privately insured men, many patients do not undergo a repeat biopsy.
The combination appears to be a more powerful predictor than mpMRI/PSA density.